Nr. 1, 2008 - Romanian Journal of Cardiology

Ghid de diagnostic şi tratament al sindroamelor coronariene acute
fără supradenivelare de segment ST
nary intervention: results from the ARMYDA-2 (Antiplatelet therapy
for Reduction of MYocardial Damage during Angioplasty) study.
Circulation 2005;111:2099-2106.
224. von Beckerath N, Taubert D, Pogatsa-Murray G, Schomig E, Kastrati
A,Schomig A. Absorption, metabolization, and antiplatelet effects of
300-, 600-, and 900-mg loading doses of clopidogrel: results of the
ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen:
Choose Between 3 High Oral Doses for Immediate Clopido grel
Effect)Trial. Circulation 2005; 112:2946-2950.
225. Hochholzer W, Trenk D, Bestehorn HP, Fischer B, Valina CM, Ferenc
M, Gick M, Caputo A, Buttner HJ, Neumann FJ. Impact of the degree
of peri-interventional platelet inhibition after loading with clopidogrel
on early clinical outcome of elective coronary stent placement. J Am
Coll Cardiol 2006;48:1742-1750.
226. SzukT, Gyongyosi M, Homorodi N, Kristof E, Kiraly C, Edes IF,
Facsko A, Pavo N, Sodeck G, Strehblow C, Farhan S, Maurer G, Glogar
D, Domanovits H, Huber K, Edes I. Effect of timing of clopidogrel
admi nis tration on 30-day clinical outcomes: 300-mg loading dose
immediately after coronary stenting versus pretreatment 6 to 24 h
before stenting in a large unselected patient cohort. Am Heart J 2007;
153:289-295.
227. SYMPHONY Investigators. Comparison of sibrafiban with aspirin for
prevention of cardiovascular events after acute coronary syndromes:
a randomised trial. The SYMPHONY Investigators. Sibrafiban versus
Aspirin to Yield Maximum Protection from Ischemic Heart Events
Post-acute Coronary Syndromes. Lancet 2000;355:337-345.
228. Topol EJ, Easton D, Harrington RA, Amarenco P, Califf RM,Graffagnino
C, Davis S, Diener HC, Ferguson J, Fitzgerald D,Granett J, Shuaib A,
Koudstaal PJ, Theroux P, Van de Werf F,Sigmon K, Pieper K, Vallee
M, Willerson JT. Randomized, double-blind,placebo-controlled, international
trial of the oral IIb/IIIa antagonist lotrafiban in coronary and
cerebrovascular disease. Circulation 2003;108:399-406.
229. Boersma E, Harrington RA, Moliterno DJ, White H, Theroux P, Van
deWerf F, de Torbal A, Armstrong PW, Wallentin LC, Wilcox RG,
Simes J, Califf RM, Topol EJ, Simoons ML. Platelet glycoprotein IIb/
IIIa inhi bitors in acute coronary syndromes: a meta-analysis of all
major randomized clinical trials. Lancet 2002;359:189-198.
230. Roffi M, Chew DP, Mukherjee D, Bhatt DL, White JA, Moliterno DJ,
Heeschen C, Hamm CW, Robbins MA, Kleiman NS, Theroux P, White
HD, Topol EJ. Platelet glycoprotein IIb/IIIa inhibition in acute cor o-
nary syndromes. Gradient of benefit related to the revascularization
strategy. Eur Heart J 2002;23:1441-1448.
231. Boersma E, Akkerhuis KM, Theroux P, Califf RM, Topol EJ, Simoons
ML. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation
acute coronary syndromes: early benefit during medical treatment
only, with additional protection during percutaneous coronary
interven tion. Circulation 1999;100:2045-2048.
232. Kong DF, Califf RM, Miller DP, Moliterno DJ, White HD, Harrington
RA, Tcheng JE, Lincoff AM, Hasselblad V, Topol EJ. Clinical outcomes
of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin
in ischemic heart disease. Circulation 1998;98:2829-2835.
233. Roffi M, Chew DP, Mukherjee D, Bhatt DL, White JA, Heeschen
C, Hamm CW, Moliterno DJ, Califf RM, White HD, Kleiman NS,
Theroux P,Topol EJ. Platelet glycoprotein IIb/IIIa inhibitors reduce
mor tality in dia betic patients with non-ST-segment-elevation acute
coronary syndromes. Circulation 2001;104:2767-2771.
234. Simoons ML. Effect of glycoprotein IIb/IIIa receptor blocker abciximab
on outcome in patients with acute coronary syndromes without early
coronary revascularisation: the GUSTO IV-ACS randomised trial.
Lancet 2001;357:1915-1924.
235. PURSUIT Investigators. Inhibition of platelet glycoprotein IIb/IIIa
with eptifibatide in patients with acute coronary syndromes. The
PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable
Angina: Receptor Suppression Using Integrilin Therapy. N Engl J
Med 1998;339:436-443.
236. PRISM Investigators. A comparison of aspirin plus tirofiban with
aspirin plus heparin for unstable angina. Platelet Receptor Inhibition
in Ischemic Syndrome Management (PRISM) Study Investigators. N
Engl J Med1998;338:1498-1505.
237. PRISM PLUS Investigators. Inhibition of the platelet glycoprotein
Revista Română de Cardiologie
Vol. XXIII, Nr. 1, 2008
IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave
myocar dial infarction. Platelet Receptor Inhibition in Ischemic Syndrome
Manage ment in Patients Limited by Unstable Signs and Symptoms
(PRISM-PLUS) Study Investigators. N Engl J Med 1998;338:1488-
1497.
238. Kong DF, Hasselblad V, Harrington RA, White HD, Tcheng JE,
Kandzari DE,Topol EJ, Califf RM. Meta-analysis of survival with
platelet glycoproteinIIb/IIIa antagonists for percutaneous coronary
inter ventions. Am J Cardiol 2003; 92:651-655.
239. EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade
and low-dose heparin during percutaneous coronary revascularization.
The EPILOG Investigators. N Engl J Med 1997;336:1689-1696.
240. EPISTENT Investigators. Randomised placebo-controlled and ball o-
on-angioplasty-controlled trial to assess safety of coronary stent ing
with use of platelet glycoprotein-IIb/IIIa blockade. The EPISTENT
Inves tigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting.
Lancet 1998;352:87-92.
241. Lincoff AM, Califf RM, Anderson KM, Weisman HF, Aguirre FV,
Kleiman NS, Harrington RA, Topol EJ. Evidence for prevention
of death and myocardial infarction with platelet membrane glycopro
teinIIb/IIIa receptor blockade by abciximab (c7E3 Fab) among
patients with unstable angina undergoing percutaneous coronary
revasculariza tion. EPIC Investigators. Evaluation of 7E3 in Preventing
Ischemic Com plications. J Am Coll Cardiol 1997;30:149-156.
242. Anderson KM, Califf RM, Stone GW, Neumann FJ, Montalescot
G,Miller DP, Ferguson JJ III, Willerson JT, Weisman HF, Topol EJ.
Long-term mortality benefit with abciximab in patients undergoing
percutaneous coronary intervention. J Am Coll Cardiol 2001;37:2059-
2065.
243. CAPTURE Investigators. Randomised placebo-controlled trial of
abcixi mab before and during coronary intervention in refractory
unstable angina: the CAPTURE Study. Lancet 1997;349:1429-1435.
244. Topol EJ, Moliterno DJ, Herrmann HC, Powers ER, Grines CL, Cohen
DJ Cohen EA, Bertrand M, Neumann FJ, Stone GW, DiBattiste PM,
Demopoulos L. Comparison of two platelet glycoprotein IIb/IIIa
inhibi tors, tirofiban and abciximab, for the prevention of ischemic
events with percutaneous coronary revascularization. N Engl J Med
2001;344:1888-1894.
245. Moliterno DJ, Yakubov SJ, DiBattiste PM, Herrmann HC, Stone GW,
Macaya C, Neumann FJ, Ardissino D, Bassand JP, Borzi L, Yeung AC,
Harris KA, Demopoulos LA, Topol EJ. Outcomes at 6 months for the
direct comparison of tirofiban and abciximab during percutaneous
cor o nary revascularisation with stent placement: the TARGET followup
study. Lancet 2002;360:355-360.
246. IMPACT-I I Investigators. Randomised placebo-controlled trial of
effect of eptifibatide on complications of percutaneous coronary intervention:
IMPACT-I I. Integrilin to Minimise Platelet Aggregation and
Coronary Thrombosis-II. Lancet 1997;349:1422-1428.
247. ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned
coronary stent implantation (ESPRIT): a randomised, placebo-controlled
trial. Lancet 2000;356:2037-2044.
248. RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade
with tirofiban on adverse cardiac events in patients with unstable
angina or acute myocardial infarction undergoing coronary
angio plasty. The RESTORE Investigators. Randomized Efficacy Study
of Tiro fiban for Outcomes and REstenosis. Circulation 1997;96:1445-
1453.
249. Valgimigli M, Percoco G, Barbieri D, Ferrari F, Guardigli G, Parrinello
G, Soukhomovskaia O, Ferrari R. The additive value of tirofiban
adminis tered with the high-dose bolus in the prevention of ischemic
compli cations during high-risk coronary angioplasty: the ADVANCE
Trial. J Am Coll Cardiol 2004;44:14-19.
250. Giugliano RP, Newby LK, Harrington RA, Gibson CM, Van de Werf
F, Armstrong P, Montalescot G, Gilbert J, Strony JT, Califf RM, Braunwald
E. The early glycoprotein IIb/IIIa inhibition in non-ST-segment
elevation acute coronary syndrome (EARLY ACS) trial: a randomized
placebo-controlled trial evaluating the clinical benefits of early frontloaded
eptifibatide in the treatment of patients with non-ST-segment
elevation acute coronary syndrome—study design and rationale. Am
Heart J 2005;149:994-1002.